Aurinia Pharmaceuticals Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: Victoria Canada (2012)

Organization Overview

First Clinical Trial
2012
NCT00244842
First Marketed Drug
2021
voclosporin (Lupkynis)
First NDA Approval
2021
voclosporin (Lupkynis)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AURINIA | Aurinia Pharmaceuticals Inc.

Active Ingredients

Marketed Drugs (1)

voclosporin (Lupkynis) (2021 NDA)

Drugs in Phase 3 Trials (3)

cyclosporine (sandimmune) (2 trials)

tacrolimus (prograf) (3 trials)

voclosporin (Lupkynis) (17 trials)

Drugs in Phase 1 Trials (1)

simvastatin (zocor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 2)

Glomerulosclerosis, Focal Segmental (Phase 2)

Keratoconjunctivitis (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Kidney Diseases (Phase 2)

Lupus Nephritis (Phase 3)

Nephritis (Phase 3)

Psoriasis (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 4